Key result
Vemurafenib exhibited potent anti-EV-A71 effects in vitro by interrupting genome replication and virus assembly, with an EC50 at nanomolar concentrations.
Why the study?
Enterovirus A71 infection causes hand, foot and mouth disease with potential severe neurological complications, but treatment options are lacking.
Does vemurafenib inhibit Enterovirus A71 replication and assembly in vitro?
Does vemurafenib inhibit Enterovirus A71 replication and assembly in vitro?
Vemurafenib demonstrates potent in vitro antiviral activity against Enterovirus A71 by interrupting genome replication and assembly.
Answers are grounded in this paper and cite their sources.
Vemurafenib inhibits EV-A71 replication in vitro; leaves open clinical utility pending randomized trials.
Enterovirus A71 (EV-A71) infection is a major cause of hand, foot and mouth disease (HFMD) which may be occasionally associated with severe neurological complications. There are currently a lack of treatment options for EV-A71 infection. The Raf-MEK-ERK signaling pathway, in addition to its critical importance in the regulation of cell growth, differentiation and survival, has been shown to be essential for virus replication. In this study, we investigated the anti-EV-A71 activity of vemurafenib, a clinically approved B-Raf inhibitor used in the treatment of late stage melanoma. Vemurafenib exhibits potent anti-EV-A71 effect in cytopathic effect inhibition and viral load reduction assays, with half maximal effective concentration (EC50) at nanomolar concentration. Mechanistically, vemurafenib interrupts both EV-A71 genome replication and assembly. These findings expand the list of potential antiviral candidates of anti-EV-A71 therapeutics.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2022) studied Enterovirus A71 (EV-A71) infection. Vemurafenib was evaluated on Cytopathic effect inhibition and viral load reduction. Vemurafenib exhibited potent anti-EV-A71 effects in vitro by interrupting genome replication and virus assembly, with an EC50 at nanomolar concentrations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: